Insider Selling: Immunome (NASDAQ:IMNM) Director Sells $2,134,176.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 101,050 shares of Immunome stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $21.12, for a total transaction of $2,134,176.00. Following the sale, the director owned 308,504 shares of the company’s stock, valued at approximately $6,515,604.48. The trade was a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The stock was sold at an average price of $22.59, for a total value of $2,259,000.00.

Immunome Price Performance

NASDAQ IMNM opened at $23.61 on Friday. Immunome, Inc. has a 1-year low of $7.96 and a 1-year high of $27.65. The company has a market capitalization of $2.67 billion, a P/E ratio of -9.92 and a beta of 2.07. The business has a 50 day moving average price of $20.96 and a 200 day moving average price of $21.80.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.12. On average, research analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on IMNM. Leerink Partners decreased their price objective on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research report on Friday, May 15th. Wall Street Zen downgraded shares of Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Immunome in a research report on Wednesday, May 13th. Wedbush reaffirmed an “outperform” rating and issued a $31.00 price target on shares of Immunome in a report on Friday, June 12th. Finally, Truist Financial increased their price target on shares of Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. Twelve research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $33.17.

Institutional Trading of Immunome

Several institutional investors and hedge funds have recently made changes to their positions in the stock. KBC Group NV acquired a new stake in shares of Immunome during the first quarter valued at $60,000. BNP Paribas Financial Markets lifted its holdings in Immunome by 81.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after purchasing an additional 2,909 shares in the last quarter. Strs Ohio acquired a new stake in shares of Immunome during the 4th quarter worth about $64,000. Tower Research Capital LLC TRC boosted its stake in shares of Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after purchasing an additional 3,802 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Immunome during the third quarter worth about $76,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.